Tower Research Capital (TRC)’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.4K | Sell |
1,171
-1,444
| -55% | -$49.3K | ﹤0.01% | 2874 |
|
|
2026
Q1 | $86.5K | Buy |
2,615
+451
| +21% | +$19.1K | ﹤0.01% | 2302 |
|
|
2025
Q4 | $100K | Buy |
2,164
+940
| +77% | +$39.3K | ﹤0.01% | 1944 |
|
|
2025
Q3 | $42.8K | Sell |
1,224
-2,327
| -66% | -$80.9K | ﹤0.01% | 2649 |
|
|
2025
Q2 | $105K | Buy |
3,551
+2,899
| +445% | +$82.7K | ﹤0.01% | 2338 |
|
|
2025
Q1 | $19.5K | Sell |
652
-11,059
| -94% | -$338K | ﹤0.01% | 2992 |
|
|
2024
Q4 | $336K | Buy |
11,711
+7,000
| +149% | +$232K | 0.01% | 1320 |
|
|
2024
Q3 | $182K | Sell |
4,711
-5,539
| -54% | -$198K | ﹤0.01% | 1715 |
|
|
2024
Q2 | $330K | Buy |
10,250
+9,115
| +803% | +$316K | 0.01% | 1672 |
|
|
2024
Q1 | $44.1K | Buy |
1,135
+39
| +4% | +$1.36K | ﹤0.01% | 2372 |
|
|
2023
Q4 | $33.7K | Buy |
1,096
+174
| +19% | +$4.36K | ﹤0.01% | 3355 |
|
|
2023
Q3 | $20.6K | Sell |
922
-2,396
| -72% | -$54.6K | ﹤0.01% | 3342 |
|
|
2023
Q2 | $71.3K | Buy |
3,318
+2,408
| +265% | +$54.7K | ﹤0.01% | 2293 |
|
|
2023
Q1 | $22K | Buy |
910
+609
| +202% | +$16.1K | ﹤0.01% | 3322 |
|
|
2022
Q4 | $7K | Sell |
301
-1,497
| -83% | -$30.2K | ﹤0.01% | 4543 |
|
|
2022
Q3 | $29K | Sell |
1,798
-23,741
| -93% | -$419K | ﹤0.01% | 3618 |
|
|
2022
Q2 | $452K | Buy |
25,539
+25,054
| +5,166% | +$421K | 0.01% | 1201 |
|
|
2022
Q1 | $10K | Sell |
485
-2,529
| -84% | -$47.8K | ﹤0.01% | 4290 |
|
|
2021
Q4 | $56K | Buy |
3,014
+1,206
| +67% | +$23.5K | ﹤0.01% | 2674 |
|
|
2021
Q3 | $36K | Sell |
1,808
-3,458
| -66% | -$74.8K | ﹤0.01% | 3217 |
|
|
2021
Q2 | $124K | Buy |
5,266
+2,992
| +132% | +$69.1K | ﹤0.01% | 2250 |
|
|
2021
Q1 | $54K | Buy |
2,274
+1,495
| +192% | +$35.5K | ﹤0.01% | 3054 |
|
|
2020
Q4 | $16K | Sell |
779
-24,743
| -97% | -$483K | ﹤0.01% | 4001 |
|
|
2020
Q3 | $531K | Buy |
25,522
+16,734
| +190% | +$302K | 0.01% | 1611 |
|
|
2020
Q2 | $154K | Buy |
+8,788
| New | +$172K | 0.01% | 2043 |
|
|
2019
Q4 | – | Sell |
-337
| Closed | -$4K | – | 3648 |
|
|
2019
Q3 | $4K | Sell |
337
-734
| -69% | -$8.38K | ﹤0.01% | 3396 |
|
|
2019
Q2 | $14K | Sell |
1,071
-4,908
| -82% | -$65.6K | ﹤0.01% | 2371 |
|
|
2019
Q1 | $90K | Buy |
+5,979
| New | +$95.8K | 0.01% | 1480 |
|
|
2018
Q4 | – | Sell |
-447
| Closed | -$7K | – | 3873 |
|
|
2018
Q3 | $7K | Sell |
447
-1,668
| -79% | -$29.6K | ﹤0.01% | 2944 |
|
|
2018
Q2 | $50K | Buy |
+2,115
| New | +$52K | ﹤0.01% | 1847 |
|
|
2017
Q4 | – | Sell |
-3,731
| Closed | -$39K | – | 3574 |
|
|
2017
Q3 | $39K | Buy |
3,731
+3,631
| +3,631% | +$40K | ﹤0.01% | 2195 |
|
|
2017
Q2 | $1K | Sell |
100
-4,228
| -98% | -$41.8K | ﹤0.01% | 2465 |
|
|
2017
Q1 | $44K | Buy |
4,328
+4,233
| +4,456% | +$62.9K | ﹤0.01% | 798 |
|
|
2016
Q4 | $1K | Buy |
+95
| New | +$1.58K | ﹤0.01% | 3583 |
|
|
2016
Q2 | – | Sell |
-577
| Closed | -$10K | – | 4484 |
|
|
2016
Q1 | $10K | Buy |
577
+327
| +131% | +$5.94K | ﹤0.01% | 1943 |
|
|
2015
Q4 | $7K | Buy |
+250
| New | +$5.27K | ﹤0.01% | 2548 |
|
|
2015
Q3 | – | Sell |
-506
| Closed | -$9K | – | 4088 |
|
|
2015
Q2 | $9K | Buy |
+506
| New | +$8.75K | ﹤0.01% | 2784 |
|
Other funds holding COLL
JT
EAM
Tower Research Capital (TRC)'s COLL Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Collegium Pharmaceutical (COLL) stake by 55% in Q2 2026, selling an estimated $49.3K and leaving 1,171 shares worth $42.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2874.
Tower Research Capital (TRC) first reported a position in COLL in Q2 2015 and has held it in 37 quarters since. The position peaked at $531K in Q3 2020. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- Tower Research Capital (TRC) held 1,171 shares of Collegium Pharmaceutical worth $42.4K as of Q2 2026.
- Tower Research Capital (TRC) sold 1,444 Collegium Pharmaceutical shares in Q2 2026, an estimated $49.3K.
- Collegium Pharmaceutical made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2874 holding.
- Tower Research Capital (TRC) first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 37 quarters since.
- Tower Research Capital (TRC)'s Collegium Pharmaceutical position peaked at $531K in Q3 2020.
- 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.